Ieq Capital LLC Acquires 51,637 Shares of Natera, Inc. (NASDAQ:NTRA)

Ieq Capital LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 551.2% in the 4th quarter, HoldingsChannel reports. The firm owned 61,005 shares of the medical research company’s stock after acquiring an additional 51,637 shares during the quarter. Ieq Capital LLC’s holdings in Natera were worth $9,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Creative Planning increased its holdings in Natera by 18.3% during the third quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after buying an additional 904 shares during the last quarter. Private Advisor Group LLC grew its position in shares of Natera by 5.2% during the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 135 shares during the period. Lecap Asset Management Ltd. increased its stake in shares of Natera by 8.2% during the 3rd quarter. Lecap Asset Management Ltd. now owns 7,003 shares of the medical research company’s stock worth $889,000 after purchasing an additional 531 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Natera by 9,755.3% in the 3rd quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after purchasing an additional 14,828 shares during the period. Finally, Zweig DiMenna Associates LLC raised its holdings in shares of Natera by 213.0% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 242,625 shares of the medical research company’s stock worth $30,801,000 after purchasing an additional 165,100 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Down 2.6 %

Shares of NASDAQ:NTRA opened at $168.19 on Friday. The firm has a market capitalization of $22.20 billion, a P/E ratio of -95.56 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a 50 day moving average price of $168.06 and a 200-day moving average price of $144.78. Natera, Inc. has a 52-week low of $69.14 and a 52-week high of $183.00.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NTRA shares. Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. JPMorgan Chase & Co. boosted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Sanford C. Bernstein increased their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, The Goldman Sachs Group boosted their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $170.94.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 4,858 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $166.59, for a total value of $809,294.22. Following the sale, the insider now directly owns 114,912 shares of the company’s stock, valued at $19,143,190.08. This represents a 4.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 663 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.